Ayuda
Ir al contenido

Dialnet


Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?

    1. [1] Hospital Universitario Son Espases

      Hospital Universitario Son Espases

      Palma de Mallorca, España

    2. [2] Hospital de Fuenlabrada

      Hospital de Fuenlabrada

      Fuenlabrada, España

    3. [3] Hospital General Universitario de Valencia

      Hospital General Universitario de Valencia

      Valencia, España

    4. [4] Hospital General Universitario Gregorio Marañón

      Hospital General Universitario Gregorio Marañón

      Madrid, España

    5. [5] Hospital Virgen de la Arrixaca

      Hospital Virgen de la Arrixaca

      Murcia, España

    6. [6] Memorial Sloan Kettering Cancer Center

      Memorial Sloan Kettering Cancer Center

      Estados Unidos

    7. [7] Hospital Universitario Virgen del Rocío

      Hospital Universitario Virgen del Rocío

      Sevilla, España

    8. [8] Hospital Quirón de Torrevieja, España
    9. [9] MD Anderson Cancer Center Madrid, España
    10. [10] Hospital Universitario de Torrecárdenas, España
    11. [11] Hospital de Sant Joan de Espi Moises Broggi, España
  • Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 11 (November 2017), 2017, págs. 1388-1392
  • Idioma: inglés
  • Texto completo no disponible (Saber más ...)
  • Resumen
    • Background Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei and appendix tumours are widespread in the world. It is unclear what should be the attitude in elderly patients.

      Methods This retrospective multicenter study collected the database from ten Spanish centers from Spanish Group of Peritoneal Cancer Surgery. The study period was between November 2002 and March 2014. Seventeen patients with age greater than or equal to 75 years with peritoneal carcinomatosis from pseudomyxoma peritonei and appendix tumours met the selection criteria for the study. Outcomes in terms of morbidity and mortality such as disease-free and overall survival were analyzed.

      Results Median PCI was 16 (range 6–39). Ten postoperative adverse events were detected in nine patients (44.4%). 28% were grade I–II and 17% were grade III–IV. Disease-free survival at 1 and 3 years was 67 and 44%, respectively. Overall survival at 1 and 3 years was 100 and 88%, respectively. Only cytoreduction was related to worst disease free survival after univariate (p = 0.007) and multivariate (OR 11.639, 95% CI 1.24–109.74, p = 0.03) analyses. Cytoreduction was related to the worst overall survival after univariate analysis (p = 0.046).

      Conclusion Cytoreductive surgery and HIPEC for pseudomyxoma peritonei and appendix tumours in elderly patients it is a procedure with feasible postoperative morbi-mortality and survival outcomes.


Fundación Dialnet

Dialnet Plus

  • Más información sobre Dialnet Plus

Opciones de compartir

Opciones de entorno